WeMed Medical Unveils “Hand-Eye-Brain” Trinity Interventional Solution At EuroPCR 2026 in Paris

PARIS, France – May 21, 2026 – WeMed Medical, a leading innovator in high-end interventional medical devices, today announced the European debut of its "Hand-Eye-Brain" Trinity Interventional Collaborative Solution at EuroPCR 2026. The groundbreaking system is being showcased at the Palais des Congrès in Paris from May 19 to 22.

As one of the world's most influential academic events in interventional cardiovascular medicine, this year's EuroPCR centers on the theme "Education Saves Lives: Preventing and Managing Complications," underscoring the critical role of evidence-based practice and knowledge sharing in elevating the quality of interventional care.

At the congress, WeMed Medical is showcasing its flagship ETcath® Interventional Surgical Robot alongside its advanced line of DSA angiography systems. Together, these proprietary technologies form the "Hand-Eye-Brain" solution-a fully integrated collaborative system developed in China-demonstrating the rising global prominence and innovation capabilities of Chinese medical device manufacturing.

Three Core Pillars of the ETcath® Interventional Robot

The ETcath® robot integrates multi-modality imaging, precision motion control, and AI-driven analytics into an intelligent, end-to-end surgical solution. Its three defining pillars include:

• "See-Through Eye" – Ultra-High-Definition Imaging for Precision Insight: By integrating proprietary DSA technology with advanced AI algorithms, the system enables real-time multi-modality image fusion and automatically identifies lesions with 0.1mm accuracy. This delivers clarity far beyond the naked eye, providing surgeons with an ultra-HD navigation map for precise lesion localization.
• "Precision Hand" – Sub-Millimeter Control with Tactile Force Feedback: Utilizing a master-slave, console-based architecture, the robot achieves motion control at the sub-millimeter level. Equipped with a 0.01N ultra-sensitive tactile feedback system, it faithfully replicates a physician's natural "hand feel," effectively eliminating hand tremors and significantly enhancing procedural safety and stability.
• "Intelligent Brain" – AI-Enabled Clinical Decision Support: Powered by a vast clinical dataset, the system generates surgical planning models in seconds, analyzes real-time imaging data, and offers intelligent decision support. This drastically shortens the learning curve for physicians and facilitates the deployment of high-quality medical resources to primary healthcare settings.

Next-Generation DSA Angiography System

WeMed Medical's DSA angiography system features an intelligent supercomputing platform driven by ultra-high-definition imaging and smart algorithms. The system enables faster, more intuitive image recognition and diagnostic assistance, delivering crystal-clear, real-time vascular imaging during complex interventional procedures.

Key intelligent imaging capabilities include:

• Image Acquisition: Intelligent algorithm-assisted technology significantly improves data quality and consistency from the outset.
• Image Preprocessing: Automatically filters out image noise while optimizing vascular contrast.
• Image Registration: Advanced AI accurately aligns Mask images with Live images via smart-matching algorithms.

Customizable Post-Processing: Offers a wide range of tailorable post-processing functions to suit individual physician preferences.

Additionally, the DSA system integrates premium core hardware to ensure clear visualization of complex vascular structures and subtle lesion details, maintaining the high-resolution support vital for clinical diagnosis and surgical execution.

A Commitment to Global Collaboration and Innovation

"The core ethos of EuroPCR-the open exchange of scientific knowledge and clinical experience-closely aligns with WeMed Medical's corporate philosophy," a company spokesperson stated. "As the conference champions, sharing and communication benefit the entire medical community and continuously drive the quality of interventional practice forward."

By participating in EuroPCR 2026, WeMed Medical not only highlights the innovation strength of China's high-end medical sector but also deepens its global market footprint. With smarter, more efficient, and safer solutions, the company is actively advancing the frontiers of global interventional medicine.

Looking Ahead

Upholding its mission of "Safeguarding lives through technological innovation," WeMed Medical will continue to ramp up R&D investment and drive growth through technological breakthroughs. Moving forward, the company aims to strengthen international partnerships, accelerate the global adoption of cutting-edge medical technologies, and foster the intelligent evolution of healthcare. By bringing more precise, safer, and accessible treatment options to patients worldwide, WeMed Medical is dedicated to elevating the standard of global healthcare.